7.3 Neurological Emergencies and Neuromuscular Disorders

7.3 Neurological Emergencies and Neuromuscular Disorders

Acute neurological emergencies demand rapid clinical recognition, precise physical assessment, and decisive evidence-based interventions. Neuronal tissue possesses minimal endogenous energy reserves and relies entirely on a continuous supply of oxygen and glucose delivered by cerebral blood flow. In conditions such as acute stroke, malignant intracranial hypertension, status epilepticus, and neuromuscular respiratory failure, delay in clinical nursing interventions directly translates into irreversible neuronal loss.

---

Stroke: Ischemic vs. Hemorrhagic Syndromes & Acute Protocols

Stroke (cerebrovascular accident) is characterized by the sudden onset of focal neurological deficits resulting from vascular disruption. Strokes are categorized into Ischemic Stroke (accounting for approximately 85% of cases), caused by thrombotic or embolic occlusion of a cerebral artery, and Hemorrhagic Stroke (accounting for approximately 15% of cases), resulting from intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH).

Clinical Presentation & The FAST Screen

• Face Drooping: Asymmetrical smile, facial droop, or flattening of the nasolabial fold.
• Arm Weakness: Pronator drift; patient closes eyes and holds both arms straight forward with palms up for 10 seconds; one arm involuntarily drifts downward or turns inward.
• Speech Difficulty: Dysarthria (slurred speech), expressive aphasia (Broca's—inability to produce fluent speech), or receptive aphasia (Wernicke's—inability to comprehend language).
• Time to Act: Determine the exact time of "Last Known Well" (the last time the patient was observed at baseline neurological status). If the patient awakens with stroke deficits, the time of onset is defined as the time the patient was last seen awake and normal.

Emergent Diagnostic Workup

• Non-Contrast Head CT Scan: The absolute initial diagnostic test of choice. Must be performed within 20 minutes of hospital arrival and interpreted within 45 minutes. The non-contrast CT immediately differentiates ischemic stroke from acute hemorrhagic stroke (extravasated blood appears hyperdense [bright white] on non-contrast CT). Early ischemic changes may not appear on CT for 6 to 12 hours, but ruling out intracranial blood is mandatory before initiating thrombolysis.
• Fingerstick Blood Glucose: Performed immediately to rule out hypoglycemia (blood glucose < 60 mg/dL), which can precisely mimic acute focal ischemic stroke deficits.

Intravenous Thrombolysis: Alteplase (tPA) Protocol

Recombinant tissue plasminogen activator (Alteplase / IV tPA) initiates local fibrinolysis by binding to fibrin within a thrombus and converting entrapped plasminogen to plasmin, thereby dissolving the occluding blood clot.

• Therapeutic Window: Administered within 3.0 hours of symptom onset (extended to 4.5 hours in eligible patients meeting strict criteria per American Heart Association / American Stroke Association guidelines).
• Dosage Calculation: 0.9 mg/kg total dose (maximum total dose: 90 mg). Administer 10% of the calculated total dose as an immediate IV bolus over 1 minute, and infuse the remaining 90% continuously over 60 minutes using an infusion pump.

Absolute Contraindications & Exclusion Criteria for IV Alteplase (tPA):
- Evidence of acute intracranial hemorrhage on non-contrast CT.
- History of previous intracranial hemorrhage at any time.
- Significant head trauma or ischemic stroke within the preceding 3 months.
- Major surgical procedure or serious systemic trauma within the preceding 14 days.
- Active internal bleeding or gastrointestinal/urinary hemorrhage within 21 days.
- Severe uncontrolled hypertension: Systolic BP > 185 mmHg or Diastolic BP > 110 mmHg.
- Severe thrombocytopenia: Platelet count < 100,000/mm³.
- Coagulopathy: Current anticoagulant therapy with INR > 1.7, PT > 15 seconds, or aPTT > 40 seconds.

Blood Pressure Control Before and After Alteplase

Elevated blood pressure markedly increases the risk of symptomatic intracranial hemorrhagic transformation following tPA administration.

• Pre-tPA Blood Pressure Target: Blood pressure must be lowered to < 185 mmHg systolic and < 110 mmHg diastolic prior to initiating the alteplase infusion. Administer IV Labetalol (10 to 20 mg IV over 1 to 2 minutes, repeatable once) or IV Nicardipine continuous infusion (titrated from 5 mg/hr up to 15 mg/hr). If blood pressure cannot be controlled below 185/110 mmHg, tPA is strictly contraindicated.
• Post-tPA Blood Pressure Maintenance: Blood pressure must be maintained < 180 mmHg systolic and < 105 mmHg diastolic continuously during the infusion and for at least 24 hours post-infusion.

Nursing Care & Neurological Monitoring Post-tPA

• Perform comprehensive neurological assessments (using the NIH Stroke Scale) and vital signs monitoring:
  • Every 15 minutes during the 60-minute infusion and for the first 2 hours post-infusion.
  • Every 30 minutes for the subsequent 6 hours.
  • Every 1 hour for the remaining 16 hours (completing 24 hours of critical monitoring).
• EMERGENCY CESSATION PROTOCOL: If the patient develops sudden severe headache, acute nausea or vomiting, acute hypertension, or an acute decline in neurological status (drop in GCS or increase in NIHSS >= 4 points), immediately stop the alteplase infusion, summon the physician, and obtain a stat non-contrast head CT to evaluate for catastrophic intracerebral hemorrhage.
• Avoid inserting invasive catheters (nasogastric tubes, indwelling urinary catheters, arterial lines) for at least 24 hours unless clinically unavoidable.
• Withhold all antiplatelet (aspirin, clopidogrel) and anticoagulant agents for 24 hours following tPA administration until a follow-up head CT at 24 hours confirms the complete absence of hemorrhage.

Subarachnoid Hemorrhage (SAH)

Subarachnoid hemorrhage typically results from the rupture of an intracranial saccular (berry) aneurysm located in the arterial Circle of Willis.

• Clinical Presentation: Classically described as the "worst headache of my life" (thunderclap headache), characterized by instantaneous, explosive peak intensity within seconds. Accompanied by transient loss of consciousness, photophobia, nausea, vomiting, and signs of meningeal irritation: nuchal rigidity, positive Kernig's sign (pain and resistance when extending the knee with hip flexed at 90 degrees), and positive Brudzinski's sign (involuntary flexion of hips and knees when the neck is passively flexed).
• Delayed Cerebral Vasospasm: A severe complication occurring typically between days 4 and 14 post-hemorrhage, wherein breakdown products of subarachnoid blood induce severe arterial spasm, causing secondary ischemic infarction.
• Pharmacological Prophylaxis: Administer Nimodipine (60 mg PO/NG every 4 hours for 21 consecutive days). Nimodipine is a lipophilic calcium channel blocker that readily crosses the blood-brain barrier, providing neuroprotective vasodilation and preventing ischemic neurological deficits.

---

Increased Intracranial Pressure (ICP) & Herniation Syndromes

The cranial vault is a rigid, unyielding osseous structure with a fixed internal volume. According to the Monro-Kellie Doctrine, the total intracranial volume is composed of three incompressible compartments:

1. Brain Parenchyma (approx. 80% / 1,400 mL)
2. Cerebrospinal Fluid (CSF) (approx. 10% / 150 mL)
3. Intracranial Blood Volume (approx. 10% / 150 mL) Under physiological conditions, an increase in the volume of one component is offset by a compensatory displacement or reduction in another (primarily displacement of CSF into the spinal subarachnoid space and increased venous drainage). Once these compensatory reserves are exhausted, small additional volume increases cause exponential spikes in intracranial pressure.

Pressure Dynamics & Formulas

• Normal Intracranial Pressure (ICP): 5 to 15 mmHg in a supine adult. A sustained ICP > 20 mmHg is pathological and requires immediate medical intervention.
• Cerebral Perfusion Pressure (CPP): The net pressure gradient driving blood flow and oxygen delivery to the brain tissue. $\text{CPP} = \text{Mean Arterial Pressure (MAP)} - \text{Intracranial Pressure (ICP)}$ $\text{MAP} = \frac{\text{Systolic BP} + 2(\text{Diastolic BP})}{3}$
• Normal CPP Target: 60 to 70 mmHg. A CPP < 50 mmHg results in critical cerebral ischemia, cellular hypoxia, and neuronal death. A CPP < 30 mmHg causes irreversible cellular necrosis.

The Glasgow Coma Scale (GCS)

• Clinical Interpretation: GCS scores range from 3 (deepest coma/death) to 15 (fully awake, alert, oriented). A GCS score of <= 8 defines severe head injury and coma, establishing the universal clinical maxim: "GCS of 8, intubate" to safeguard the airway against aspiration and ventilatory failure.

Clinical Progression: Early vs. Late Signs of Elevated ICP

• Earliest and Most Sensitive Sign: Altered Level of Consciousness (LOC). Subtle personality changes, restlessness, irritability, anxiety, confusion, lethargy, or delayed verbal responses.
• Headache & Emesis: Dull, throbbing headache that characteristically worsens in the morning, with coughing, or when bending over. Projectile vomiting that occurs abruptly without preceding nausea.
• Pupillary Alterations: Compression of the third cranial nerve (oculomotor nerve) causes ipsilateral pupillary sluggishness, progressing to a unilateral, fixed, dilated pupil ("blown pupil")—the classic sign of uncal herniation.
• Cushing's Triad (The Late Hallmark of Impending Brainstem Herniation):
  1. Severe Systolic Hypertension with Widening Pulse Pressure: Systolic blood pressure rises dramatically as the vasomotor center activates sympathetic vasoconstriction to overcome intracranial resistance, while diastolic pressure remains stable or declines.
  2. Profound Bradycardia: High systemic blood pressure stimulates baroreceptors in the carotid sinus and aortic arch, triggering intense compensatory vagal parasympathetic output to the heart.
  3. Irregular, Bradypneic Respirations: Cheyne-Stokes or ataxic respirations caused by direct mechanical compression of the medullary respiratory centers.

Decorticate vs. Decerebrate Posturing:
Decorticate (Flexion): Arms curled to "Core" (corticospinal tract / cerebral hemispheres)
Decerebrate (Extension): Arms extended, pronated, teeth clenched (brainstem / midbrain)
*Decerebrate indicates deeper, more catastrophic neurological deterioration*

• Decorticate Posturing (Abnormal Flexion - GCS M=3): Bilateral flexion and adduction of the upper extremities (arms held tightly curled into the chest/"core"), clenched fists, and extension, internal rotation, and plantar flexion of the lower extremities. Indicates damage to the cerebral cortex, internal capsule, or thalamus.
• Decerebrate Posturing (Abnormal Extension - GCS M=2): Rigid extension, adduction, and internal hyperpronation of the arms with wrist flexion, extended legs, and severe plantar flexion. Indicates deeper, more severe anatomical compression or injury to the midbrain or upper pons. Decerebrate posturing signifies a substantially worse prognosis.

Evidence-Based Nursing Interventions for Elevated ICP

1. Optimal Patient Positioning: Maintain the Head of Bed (HOB) elevated strictly at 30 degrees, keeping the patient's head and neck in a neutral, midline position. Avoid lateral neck rotation, extreme neck flexion, and acute hip flexion (> 90 degrees); these positions kink the internal jugular veins and increase intra-abdominal pressure, severely impeding cerebral venous return.
2. Hyperosmolar Therapy:
   • IV Mannitol (20% solution): Osmotic diuretic administered as an intermittent IV bolus (0.5 to 1.0 g/kg over 20 to 30 minutes). Creates an osmotic gradient drawing free water from swollen brain parenchymal cells into the intravascular space. NURSING REQUIREMENT: Must be infused through an in-line filter to capture microscopic crystals that form at room temperature. Check serum osmolality (hold if serum osmolality > 320 mOsm/kg to avoid acute renal tubular necrosis).
   • Hypertonic Saline (3% or 23.4% NaCl): Draws water out of edematous astrocytes while expanding circulating plasma volume and augmenting cardiac output and CPP.
3. Strict Normothermia: Hyperthermia dramatically accelerates the cerebral metabolic rate for oxygen ($CMRO_2$), triggering cerebral vasodilation and worsening ICP. Administer antipyretics and implement cooling blankets to aggressively maintain core temperature <= 37.0°C.
4. Arterial Carbon Dioxide ($PaCO_2$) Regulation: Carbon dioxide is the most potent physiological cerebral vasodilator known. Hypercapnia ($PaCO_2 > 45 \text{ mmHg}$) causes profound cerebral arterial dilation and spikes ICP. Maintain arterial $PaCO_2$ strictly within the normal physiological range (35 to 45 mmHg). Hyperventilation ($PaCO_2$ 30 to 35 mmHg) produces cerebral vasoconstriction; it is strictly restricted to short-term emergency rescue (15 to 30 minutes) during acute, active brain herniation, because prolonged vasoconstriction causes severe secondary cerebral ischemia.
5. Spreading Care Interventions: Avoid clustering nursing activities. Grouping hygiene, endotracheal suctioning, repositioning, and linen changes causes cumulative, sustained spikes in ICP. Space activities across the shift. Pre-oxygenate with 100% O2 before endotracheal suctioning, and limit suctioning duration to < 10 seconds with no more than 2 passes.

---

Seizure Management & Status Epilepticus Protocols

A seizure is an abrupt, paroxysmal, involuntary disturbance in neurological function caused by excessive, synchronous, hypersynchronous electrical discharges from cortical neurons. Status epilepticus represents the extreme clinical manifestation.

Acute Seizure Nursing Precautions & Active Interventions

• Bedside Safety Setup: High-flow oxygen apparatus, functional suction canister with rigid Yankauer catheter, oral suction tips, padded side rails, and bed maintained in the lowest position.
• Emergency Actions During an Active Generalized Tonic-Clonic Seizure:
  1. Protect from Mechanical Injury: If the patient is sitting or standing, ease them gently to the floor. Protect the head from trauma by placing a soft pillow, folded blanket, or coat under the cranium. Clear away sharp objects, bed rails, or nearby furniture.
  2. Ensure Airway Patency & Prevent Aspiration: Position the patient onto their side (lateral recovery position) to allow the tongue to fall forward and permit oral saliva and emesis to drain freely from the mouth.
  3. Loosen Restrictive Clothing: Unbutton tight collars, loosen neckties, and remove eyeglasses.
  4. STRICT SAFETY PROHIBITIONS:
     • NEVER force any object into the patient's mouth (no tongue blades, oral airways, spoons, or fingers). Forcing objects fractures teeth, causes soft-tissue lacerations, and can occlude the larynx.
     • NEVER attempt to physically restrain the patient's limbs. Restraining violent muscular spasms causes severe muscle tears, tendon avulsions, and bone fractures.
  5. Observation and Timing: Note the exact time of onset and duration. Observe the sequence of muscular involvement, direction of gaze deviation, pupillary changes, incontinence, and post-ictal orientation.

Status Epilepticus Emergency Resuscitation

Status epilepticus is clinically defined as continuous, unremitting seizure activity lasting >= 5 minutes, or two or more discrete seizures without full recovery of consciousness between episodes. Prolonged seizures produce systemic hypoxemia, hyperthermia, severe lactic acidosis, cardiac dysrhythmias, rhabdomyolysis, and excitotoxic glutamate-mediated neuronal necrosis.

• First-Line Pharmacological Therapy (Immediate Abortive):
  • Administer an intravenous benzodiazepine immediately: IV Lorazepam (Ativan) 4 mg administered at 2 mg/min (repeat once in 5 to 10 minutes if seizures persist). Lorazepam is preferred due to its extended anticonvulsant duration of action (4 to 6 hours).
  • If IV access cannot be established immediately, administer IM Midazolam (10 mg IM) into the vastus lateralis or Rectal Diazepam gel (0.2 mg/kg).
• Second-Line Pharmacological Therapy (Urgent Antiepileptic Infusion):
  • Administer a non-sedating IV antiepileptic drug immediately following or concurrently with the benzodiazepine to prevent seizure recurrence: IV Levetiracetam (Keppra) 60 mg/kg (max 4,500 mg) infused over 10 minutes, or IV Fosphenytoin 20 mg PE/kg, or IV Valproate sodium 40 mg/kg.
• Refractory Status Epilepticus (> 30 to 60 minutes): Requires continuous IV infusions of general anesthetics (Propofol, Midazolam, or Pentobarbital) with continuous bedside electroencephalographic (EEG) monitoring and endotracheal intubation.

---

Neuromuscular Disorders: Myasthenia Gravis vs. Guillain-Barré Syndrome

Neuromuscular disorders compromise the transmission of electrical impulses across peripheral nerves or neuromuscular junctions to skeletal muscle fibers, frequently culminating in life-threatening respiratory failure.

1. Myasthenia Gravis (MG)

Myasthenia Gravis is an acquired autoimmune disorder mediated by IgG autoantibodies directed against nicotinic Acetylcholine Receptors (AChR) on the postsynaptic muscle endplate (or less commonly against Muscle-Specific Kinase [MuSK]). Antibody binding accelerates receptor degradation and complement-mediated destruction of endplate folds, leaving insufficient functional receptors for acetylcholine binding.

• Clinical Hallmarks: Fluctuating, fatigable skeletal muscle weakness that characteristically worsens with repetitive physical effort or toward the end of the day, and improves noticeably following periods of physical rest.
  • Ocular Involvement: Earliest symptoms in > 50% of patients; bilateral or asymmetrical ptosis (drooping eyelids) and diplopia (double vision).
  • Bulbar Symptoms: Chewing fatigue, dysarthria (speech becomes nasal and slurred after prolonged speaking), and dysphagia with severe aspiration risk.
  • Generalized Weakness: Weakness of neck flexors and proximal limb muscles.
• Pharmacotherapy: Acetylcholinesterase inhibitors (Pyridostigmine / Mestinon) inhibit the enzyme acetylcholinesterase, prolonging acetylcholine availability in the synaptic cleft.
  • CRITICAL NURSING TIMING: Administer pyridostigmine strictly 30 to 45 minutes prior to scheduled meals. Peak drug concentration coincides with mastication, maximizing bulbar and pharyngeal muscle strength to facilitate safe swallowing and prevent aspiration.

Myasthenic Crisis vs. Cholinergic Crisis Differentiation

2. Guillain-Barré Syndrome (GBS)

Guillain-Barré syndrome is an acute, post-infectious, autoimmune polyradiculoneuropathy characterized by immune-mediated demyelination of peripheral nerves and spinal nerve roots. Molecular mimicry triggers autoantibody production following a gastrointestinal or respiratory infection (most frequently Campylobacter jejuni, Cytomegalovirus, Epstein-Barr virus, or Mycoplasma).

• Clinical Presentation: Characterized by rapidly progressive, symmetrical, ascending muscle weakness and flaccid paralysis that begins in the distal lower extremities (numbness, paresthesias, and bilateral leg weakness) and advances upward over hours to days to involve the trunk, upper extremities, cranial nerves, and respiratory musculature. Deep tendon reflexes are diminished early and progress to complete areflexia (absent knee and ankle jerks). Autonomic dysfunction is common (labile blood pressure, severe orthostatic hypotension, cardiac arrhythmias, and paralytic ileus).
• Bedside Respiratory Monitoring — The Highest Nursing Priority: As demyelination ascends to involve the intercostal nerves and phrenic nerves (innervating the diaphragm from cervical roots C3-C5), progressive hypoventilation ensues.
  • The nurse must perform serial bedside pulmonary function testing every 2 to 4 hours:
    • Forced Vital Capacity (FVC): Normal is 60 to 70 mL/kg. An FVC < 15 to 20 mL/kg indicates severe respiratory muscle exhaustion.
    • Negative Inspiratory Force (NIF): Normal is more negative than -60 cmH2O. An NIF falling to less negative than -20 to -30 cmH2O signifies critical diaphragmatic failure.
  • Clinical Rule: If FVC drops below 15 to 20 mL/kg, NIF drops below -20 cmH2O, or the patient exhibits paradoxical abdominal breathing (inward movement of abdomen on inspiration), tachypnea, or inability to count past 10 on a single breath, the nurse must prepare for immediate endotracheal intubation and mechanical ventilation. Do not wait for arterial blood gas deterioration (hypoxemia or hypercapnia) or cyanosis.
• Disease-Modifying Therapy:
  • High-Dose Intravenous Immunoglobulin (IVIG): 0.4 g/kg/day IV for 5 consecutive days.
  • Plasmapheresis (Plasma Exchange): 4 to 6 sessions every other day to physically remove circulating autoantibodies.
  • Note: Corticosteroids are ineffective in GBS and are not recommended.